Beyond the Front Line: Emerging Data for Maintenance Therapy in Pancreatic Cancer
- 24 August 2021
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (29) , 3199-3206
Abstract
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management ... Incorporation of multiagent chemotherapy has improved outcomes for patients with metastatic pancreatic ductal adenocarcinoma and a significant number of patients can now achieve durable disease con...Keywords
This publication has 46 references indexed in Scilit:
- Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinomaNature Genetics, 2015
- Comprehensive molecular characterization of urothelial bladder carcinomaNature, 2014
- Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: A phase II randomised trialEuropean Journal of Cancer, 2013
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized TrialJournal of Clinical Oncology, 2013
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapyNature Medicine, 2011
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialThe Lancet, 2010
- Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature, 2005